Search Results 1111-1120 of 18118 for monoclonal antibody

1. Ublituximab In Autoantibody Positive Immune Mediated Necrotizing Myopathy - Mayo Clinic

   About this study. This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive ...

2. An Open-label Study To Assess The Anti-Tumor Activity And Safety Of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody, In Patients With Relapsed Or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

   An Open-label Study To Assess The Anti-Tumor Activity And Safety Of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody, In Patients With Relapsed Or ...

3. Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

   Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown. Anti-immunoglobulin E therapy ...

4. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) - Doctors and departments - Mayo Clinic

   Departments and specialties. Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, ...

5. Medical Research & Education - Mayo Clinic News Network

   Antibody-drug conjugates are targeted cancer therapies. They deliver potent drugs directly into cancer cells while minimizing harm to healthy tissue. These ...

6. Hepatocellular Carcinoma (HCC) Clinical Trials - Mayo Clinic Research

   The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with ...

7. A Study Evaluating The Efficacy And Safety Of Obinutuzumab In Participants With Primary Membranous Nephropathy - Mayo Clinic

   History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the obinutuzumab infusion; ...

8. Study To Evaluate Efficacy And Safety Of Mepolizumab For Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients - Mayo Clinic

   Monoclonal antibodies: Subjects who have received any monoclonal antibody within 5 half-lives of Visit 1. Investigational medications: Subjects who have ...

9. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) Or Daratumumab, Pomalidomide And Dexamethasone (DPd) In Participants With Relapsed And Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

   Monoclonal antibody treatment within 21 days. Cytotoxic therapy within 14 days. Proteasome inhibitor therapy within 14 days -Immunomodulatory drug (IMiD) ...

10. Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) - Mayo Clinic

    Has had prior anti-cancer monoclonal antibody within 4 weeks of Study Day 1 or who has not recovered from adverse events due to agents administered >4 weeks ...